Condition: Myocarditis Acute · Cancer · Sponsor: Massachusetts General Hospital
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
This description comes directly from the study's public registry record.
Hannah K Gilman, MS · 6177261019 · hkgilman@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| MedStar Health Research Institute, Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Franciscan Health | Indianapolis, Indiana, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Maine Health | Portland, Maine, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05335928